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Introduction
Breast cancer is the most common
cancer in women, with a 33% increase
in incidence rate in 10 years', and is the
leading cause of mortality in women.
One approach that may advance the
understanding of the increased inci-
dence of breast cancer is to study the
p53 tumour suppressor gene, which
orchestrates cell cycle control, DNA
repair, apoptosis and control of angio-
genesis.i" A high frequency of muta-
tions of this tumour suppressor gene in
human cancers (mutations found in
over 50% of human cancers) reflects
the importance of its involvement in
maintaining the stability of the genome
during cellular stress. This reason has
made the gene to be best suited for
mutational spectrum analysis besides
its modest size (I Iexons, 393 amino
acids) which allows for the study of the
entire coding region. Thus, the pres-
ence of p53 mutations in human can-
cers might indicate the value of the
gene as a molecular marker for early
prognosis especially in breast cancer
since mutations in p53 result in poor
prognosis, weak response to therapy
and decreased overall survival time",
Most common p53 mutations are found
in both familial and sporadic breast
cancers'". However, the majority of
mutations in human cancers are so-
matic rather than germline. Approxi-
mately 80% of the p53 mutations are
missense point mutations which mostly
concentrate within the central DNA
binding region (codons 110-307)7. In
breast cancer cases, many investiga-
tions have concluded that the mutations
are more common in invasive ductal
breast carcinoma than in lobular can-
cers where exons 5-8 being the region
for mutation hotspots. However, mu-
tation lying outside this region or in
intronic sequences may be significant
and have been previously underesti-
mated. In addition, studies on muta-
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tions of p53 have focused on imrnuno-
histochermical analysis of p53 expres-
sion in paraffin embedded tissues". In
the present study, a molecular screen-
ing technique was applied and the p53
gene was screened for potential muta-
tions in intron 4 through exon 9 using a
non-isotopic RNAse cleavage assay
(NIRCA) analysis.
Materials and Methods
Samples: Breast tissues processed as
paraffin-embedded samples were ob-
tained in duplicate sets and were ran-
domly selected from patients with in-
vasive ductal breast carcinoma aged 18
to 62 years. A total of thirty-one tissue
samples were stained with Hematoxy-
lin and Eosin (H&E) for identification
of the cancerous regions, which was
confirmed by a pathologist, and sub-
jected to DNA extraction. Tissue sam-
ples from non-cancerous regions were
used as controls.
DNA Extraction and Amplification:
Based on the identification of the can-
cerous regions on the H&E stained
slides, DNA extraction was carried out
from the duplicate paraffin-embedded
slides using a Pin-Point DNA extrac-
tion kit (Zymo Research) according to
the manufacturer's protocols. The
DNA obtained was then subjected to
two rounds of polymerase chain reac-
tion (PCR) to amplify exons 5-9. The
T7 and T7 promoter-incorporated
primers (Ambion) were used to amplify
the target regions (exons 5-6, 7 and 8-
9). Standard PCR conditions were
optimized and performed using a Mas-
tercycler Gradient Thermocycler (Ep-
pendorf).
Non-Isotopic RNase Cleavage Assay:
Transcription of RNA was carried out
by adding 50-l50ng of the PCR prod-
uct into 4ul of transcription assay ac-
cording to the protocol suggested by
the manufacturer (Ambion). Hybridi-
zation solution was added into the re-
action mixture prior to denaturation of
the RNA duplexes at 97°C for 7 min-
utes. The hybridization of the dena-
tured RNA transcripts was then carried
out at room temperature for 5 minutes
followed by cleavage of RNA mis-
matches by RNase digestion at 37°C
for 35 minutes. The digestion reaction
was stopped by the addition of the
stop-dye. The digested fragments were
then analyzed on a 2.5% agarose gel in
IX Tris-Borate EDTA buffer at 130 V
for two hours.
DNA Sequencing Analysis: Fragments
having alterations, and one of each
fragment without alteration of the p53
gene as detected by NIRCA were sent
for automated sequencing (IBS Ge-
nome Center, UPM) to assess the reli-
ability of the methods used and also to
determine the exact locations of the
mutations.
Results and Discussion
The methods used in the study were
successfully optimized and found reli-
able to be used in establishing a p53
gene mutation screening procedure.
All of the 3 I cases of breast cancer
samples screened showed potential
mutation spots by NIRCA and when
sequenced, were confirmed to be mu-
tations. No alteration was detected
when samples from non-cancerous
regions were used. The results ob-
tained were categorized into four
groups based on the pattern and size of
the bands produced after RNase diges-
tion. Sequence analysis also revealed
the mutations to be exclusively located
in intron 7. Presently, there are no con-
firmed prognostic variables yet estab-
lished for early diagnosis of breast
cancer. Current diagnosis of breast
cancer is based on combination of tra-
ditional clinical staging (such as local
extension, size, and the presence or
absence of nodal or distant metastases),
standard histological analysis of the
tumour specimen, and expression of
hormone receptors in the tumour",
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Thus, most cases presented are nor-
mally patients with late stage of the
tumour. Recent studies on the genetic
composition of the cancer cell and
molecular biological probes in detect-
ing variations in oncogene and other
related gene expression have revealed
several putative prognostic factors in
breast cancer. Based on the the pres-
ent study, two mutation hot spots have
been identified within intron 7, a trans-
version of T to G at nucleotide 2702
(55% occurrence) and a transversion of
T to C at nucleotide 2682 (84 % occur-
rence). It is unlikely that these are
intronic polymorphisms since they
were not detected in DNA samples
from non-cancerous regions. The mu-
tations detected are believed to be lo-
cated at the splice sites which may
cause aberrant splicing of the p53
mRNAs and hence the production of a
truncated proteins.
Conclusions
To our knowledge, this is the first re-
port of a breast cancer mutation pattern
of the p53 gene in the Malaysian
population. However, a larger sample
size would be needed to enable addi-
tional information such as cancer pre-
disposition, response to therapy and
disease progression to be obtained.
Nevertheless, the mutation detection
strategy used in this study was found to
be rapid and provided a high-
throughput method for screening pur-
poses.
Benefits from the study
The results would be useful in identi-
fying the location of the mutations spe-
cifically in the Malaysian population
and a comparison to a global muta-
tional database for breast cancer can be
obtained. Analysis of the mutated
regions would give significant infor-
mation in our understanding of the
functions of the p53 gene and perhaps
contribute towards the development of
a therapy against breast cancer.
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